A carregar...
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
BACKGROUND: Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported ou...
Na minha lista:
| Publicado no: | BMC Gastroenterol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4323227/ https://ncbi.nlm.nih.gov/pubmed/25651782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0239-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|